Orthocell Valuation Multiples

Orthocell Overview

About Orthocell

Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir, which is a collagen wrap used in peripheral nerve repair; and OrthoACI, an implant used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline, such as Tendon Cell Therapy and Collagen Medical Device Platform.

Founded

2006

HQ

Employees

N/A

Website

orthocell.com.au

Sectors

BiopharmaceuticalsBioTechDeepTechHealthTech

Financials (LTM)

Revenue: $8M

EBITDA: ($7M)

EV

$170M

Valuation Multiples

Multiples.vc

Start free trial

Orthocell Financials

Orthocell reported last 12-month revenue of $8M and negative EBITDA of ($7M).

In the same LTM period, Orthocell generated $6M in gross profit, ($7M) in EBITDA losses, and had net loss of ($8M).

Orthocell P&L

In the most recent fiscal year, Orthocell reported revenue of $6M and EBITDA of ($5M).

Orthocell expects next 12-month revenue of XXX and NTM EBITDA of XXX

Orthocell Stock Performance

Orthocell has current market cap of $201M, and enterprise value of $170M.

Orthocell's stock price is $0.74.

Orthocell Valuation Multiples

Orthocell trades at 20.1x EV/Revenue multiple, and (22.6x) EV/EBITDA.

Orthocell Financial Valuation Multiples

As of April 18, 2026, Orthocell has market cap of $201M and EV of $170M.

Equity research analysts estimate Orthocell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Orthocell has a P/E ratio of (26.5x).

Orthocell Margins & Growth Rates

Orthocell's revenue in the last 12 month grew by 74%.

Orthocell's rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Orthocell's rule of X is 127% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Orthocell Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Orthocell M&A Activity

Orthocell acquired XXX companies to date.

Last acquisition by Orthocell was on XXXXXXXX, XXXXX. Orthocell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Orthocell Investment Activity

Orthocell invested in XXX companies to date.

Orthocell made its latest investment on XXXXXXXX, XXXXX. Orthocell invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).